Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 171 participants.
Also called NCT01811485
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 171 participants
- Sponsor
- Registry
-
NCT01811485
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- Japan
- Registry status
- Completed
Technical summary
Registry record NCT01811485. Randomized; quadruple masking; primary purpose treatment. Start 2013-05 (registry gives no type); primary completion 2014-02 (actual). Results posted on 2015-02-23.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Study of Efficacy and Safety LMF237 in Patients With Type 2 Diabetes Mellitus (T2DM) Inadequately Controlled With Vildagliptin Monotherapy
- Acronym
- CLMF237A1303
- Condition
- Diabetes Mellitus, Type 2
- Intervention (Drug)
- LMF237 50/250 mg
- Intervention (Drug)
- LMF237 50/500 mg
- Intervention (Drug)
- Placebo
- Lead sponsor
- Novartis Pharmaceuticals
Record details
- Record id
cardio:ct-nct01811485- Content hash
d6fb66a507b4e533864252bd6ab6ed7d265c8462e3df3510104c1fdc3936fddd